Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rifaximin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: Rifaximin. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-001856-51 Sponsor Protocol Number: 12.007 Start Date*: 2014-08-26
    Sponsor Name:Aleksander Krag
    Full Title: Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease: A randomized placebo controlled clinical trial
    Medical condition: Liver fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10016648 Fibrosis liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-006814-35 Sponsor Protocol Number: MoodBugs_Rifaximin Start Date*: 2022-09-27
    Sponsor Name:KU Leuven
    Full Title: A randomized, triple-blind, placebo-controlled study on the effect of rifaximin on psychobiological functions in healthy men
    Medical condition: Experimental study with healthy participants recruited from the general population; no vulnerable individuals or clinical groups will be involved. Our objective is to test whether rifaximin adminis...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002264-33 Sponsor Protocol Number: AH01 Start Date*: 2014-08-25
    Sponsor Name:Ole Hamberg
    Full Title: Rifaximin in alcoholic hepatitis: effects on inflammatory and metabolic markers.
    Medical condition: Alcoholic hepatitis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004871 10001624 Alcoholic hepatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021515-17 Sponsor Protocol Number: N/A Start Date*: 2010-09-30
    Sponsor Name:Imperial College London
    Full Title: RiFL: Rifaxamin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)?
    Medical condition: Non-alcoholic steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10053219 non-alcoholic steatohepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002628-96 Sponsor Protocol Number: R-RID Start Date*: 2016-09-21
    Sponsor Name:Imperial College London
    Full Title: A multi-centre, double-blind, randomised, controlled clinical trial of Rifaximin to reduce infection in patients admitted to hospital with decompensated cirrhosis
    Medical condition: Decompensated cirrhosis - liver disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-003986-42 Sponsor Protocol Number: Rifa1 Start Date*: 2008-06-18
    Sponsor Name:University Hospital of Tübingen
    Full Title: Prospective, randomised, placebo controlled, double blind monocenter trial for the prophylactic treatment of diarrhoea with rifaximin for travellers to South- and Southeast-Asia
    Medical condition: diarrhoea of travellers to South- and Southeast-Asia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021907 Infectious diarrhea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002258-36 Sponsor Protocol Number: RETIPC/01/17 Start Date*: 2017-11-21
    Sponsor Name:ALFASIGMA S.P.A.
    Full Title: A Phase II, multicentre, double-blind, randomised, placebo-controlled study of Rifaximin delayed release 400 mg tablet: clinical efficacy and safety in the prevention of post-operative endoscopic C...
    Medical condition: Post-operative endoscopic Crohn’s disease recurrence
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000515-80 Sponsor Protocol Number: RIFA-AAH Start Date*: 2012-08-29
    Sponsor Name:Juan Córdoba
    Full Title: Effects of rifaximin administration in patients with severe acute alcoholic hepatitis. Comparative pilot study.
    Medical condition: Acute alcoholic hepatitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10000649 Acute alcoholic hepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-003205-10 Sponsor Protocol Number: 12072 Start Date*: 2012-09-17
    Sponsor Name:University of Nottingham
    Full Title: A randomised placebo controlled trial of follow on Rifaximin for the prevention of relapse of Clostridium difficile associated diarrhoea.
    Medical condition: C.Difficile antibiotic-associated diarrhoeal infection
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001645-24 Sponsor Protocol Number: RECD3126 Start Date*: 2014-11-18
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction ...
    Medical condition: Treatment of active Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001644-38 Sponsor Protocol Number: RECD3125 Start Date*: 2014-11-18
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction ...
    Medical condition: Treatment of active Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002394-22 Sponsor Protocol Number: RFIB3053 Start Date*: 2013-09-26
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhoea (IBS-D)
    Medical condition: Irritable bowel syndrome (IBS) is a heterogeneous gastrointestinal (GI) disorder characterized by frequent and debilitating symptoms (e.g. diarrhoea, bloating, abdominal pain, urgency to defecate, ...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002821-24 Sponsor Protocol Number: RETIC-PD/006/2011 Start Date*: 2011-07-21
    Sponsor Name:ALFA WASSERMANN
    Full Title: Prospective pharmacodynamic study on patients with moderate, active Crohn’s disease treated with Rifaximin-EIR 400 mg tablets.
    Medical condition: Treatment of active, moderate Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002708-28 Sponsor Protocol Number: REDIV/002/17 Start Date*: 2018-02-23
    Sponsor Name:Alfasigma S.p.a
    Full Title: Rifaximin delayed release (400 mg tablet) for the prevention of recurrent acute diverticulitis and diverticular complications. A phase II, multicenter, double-blind, placebo-controlled, randomized ...
    Medical condition: Prevention of recurrent acute diverticulitis and diverticular complications
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052812 Acute diverticulitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) HU (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) PT (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-024177-39 Sponsor Protocol Number: RIBS-MIC/002/2010 Start Date*: 2011-02-01
    Sponsor Name:ALFA WASSERMANN
    Full Title: Prospective microbiological study on patients with non-constipation IBS treated with rifaximin 550 mg tablets.
    Medical condition: Non constipation Irritable Bowel Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060845 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000102-35 Sponsor Protocol Number: 35128 Start Date*: 2014-12-19
    Sponsor Name:Clinica Medica 5
    Full Title: Effect of administration "add on" of Rifaximin on portal hypertension of patients with liver cirrhosis and esophageal varices in standard therapy with propranolol
    Medical condition: Portal hypertension, liver cirrhosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004644-28 Sponsor Protocol Number: 13-129 Start Date*: Information not available in EudraCT
    Sponsor Name:RWTH Aachen University, represented by the Rector, himself, represented by the Dean of the Medical Faculty
    Full Title: Administration of Rifaximin to improve Liver Regeneration and Outcome following Major Liver Resection
    Medical condition: Patients undergoing major liver resection will be included into the study
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003722-33 Sponsor Protocol Number: REROS/001/17 Start Date*: 2018-03-02
    Sponsor Name:ALFASIGMA S.P.A.
    Full Title: Safety and Efficacy of Rifaximin Delayed Release 400 mg Tablets in Patients with Moderate-to-Severe Papulopustular Rosacea and Positive Lactulose Breath Test. A Multicenter Double-Blind, Placebo-Co...
    Medical condition: Moderate-to-Severe Papulopustular Rosacea and Positive Lactulose Breath Test
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10076537 Papulopustular rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002890-71 Sponsor Protocol Number: RifaxNK150612 Start Date*: 2012-08-16
    Sponsor Name:Flemming Bendtsen
    Full Title: Intestinal decontamination with rifaximin. Effects on the inflammatory and circulatory state in patients with cirrhosis and ascites - A randomised controlled clinical study
    Medical condition: Liver cirrhosis of any etilogy, complicated by decompensation and classified as Child-Pugh B or C
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000357-41 Sponsor Protocol Number: APC040 Start Date*: 2013-08-28
    Sponsor Name:The Alimentary Pharmabiotic Centre, University College Cork
    Full Title: Identification of the Microbiota Dependent Response to Rifaximin in Irritable Bowel Syndrome Patients
    Medical condition: Irritable Bowel Syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 09:13:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA